Overview
The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
Description
This project will use a rigorous residential laboratory design to evaluate e-cigarette withdrawal expression and experimentally determine the role of nicotine in this syndrome. Healthy adults who exclusively use e-cigarettes will undergo monitored e-cigarette abstinence over seven days (1 week) in a residential unit. The investigators will evaluate the contribution of nicotine to withdrawal expression by assigning participants to one of three conditions: active nicotine patch, placebo patch control, or no patch to control for expectancies. Standardized behavioral and biological measures associated with withdrawal including patient report, cognitive task performance, and biometrics will be collected throughout to establish a rigorous timecourse of withdrawal and evaluate the contribution of nicotine to these symptoms.
Eligibility
Inclusion criteria:
- 21-55 years old
- good general health as reviewed by study medical team
- vital signs in normal range as reviewed by study medical team
- negative urine test for illicit drug use (excluding THC) and negative breath alcohol test
- daily use of a nicotine-containing e-cigarette for at least 6 months
- no regular use of other tobacco products (e.g., smokeless products) for at least 6 months
- urine cotinine >100ng/mL (i.e., recommended cutoff for confirming current nicotine use)
- exhaled breath carbon monoxide (CO) <6ppm
- Penn State E-cigarette Dependence (PSED) score >=4, indicating mild dependence or greater
- have an interest in reducing e-cigarette use
Exclusion criteria:
- psychoactive drug use (aside from cannabis, nicotine, alcohol, caffeine) in past month
- current use of over-the-counter (OTC) or prescription medications that may impact safety
- use cannabis >2 times per week
- history of or current significant medical condition that would impact participation or safety according to the study investigators and medical staff
- current psychiatric condition or substance use disorder (aside from tobacco use disorder) that would impact participation or safety according to the study investigators and medical staff
- enrollment in another trial
- positive pregnancy test
- currently using a nicotine/tobacco cessation product
- seizure disorder or traumatic brain injury (TBI)